AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT104.61-0.64 (-0.61%) ▼|ACN175.94+0.10 (+0.06%) ▲|ADBE250.87-4.00 (-1.57%) ▼|AMAT456.67-12.19 (-2.60%) ▼|AMD509.74-11.36 (-2.18%) ▼|AMGN390.18-1.09 (-0.28%) ▼|AMT174.98-0.60 (-0.34%) ▼|AMZN251.14-1.26 (-0.50%) ▼|AVGO359.25-5.13 (-1.41%) ▼|AXP321.15-0.65 (-0.20%) ▼|BA207.29+0.81 (+0.39%) ▲|BAC62.61-0.08 (-0.13%) ▼|BKNG173.65+0.22 (+0.13%) ▲|BLK1,067.32-5.20 (-0.48%) ▼|BMY64.39-0.02 (-0.03%) ▼|BNY162.60+0.03 (+0.02%) ▲|BRK-B507.32+0.56 (+0.11%) ▲|C138.00+0.19 (+0.14%) ▲|CAT809.00-7.05 (-0.86%) ▼|CL88.66+0.65 (+0.73%) ▲|CMCSA24.74+0.15 (+0.61%) ▲|COF209.00-1.95 (-0.92%) ▼|COP137.89+1.28 (+0.94%) ▲|COST910.45+7.85 (+0.87%) ▲|CRM244.22+0.02 (+0.01%) ▲|CSCO109.31-0.12 (-0.11%) ▼|CVS96.74+1.36 (+1.42%) ▲|CVX215.32+1.50 (+0.70%) ▲|DE676.67-0.62 (-0.09%) ▼|DHR200.69-4.30 (-2.10%) ▼|DIS104.09-0.09 (-0.08%) ▼|DUK120.79+0.35 (+0.29%) ▲|EMR148.07-2.33 (-1.55%) ▼|FDX308.33-0.90 (-0.29%) ▼|GD353.93+1.25 (+0.35%) ▲|GE323.99-1.45 (-0.45%) ▼|GEV937.18-13.43 (-1.41%) ▼|GILD145.60-0.06 (-0.04%) ▼|GM84.25+0.47 (+0.56%) ▲|GOOG327.17-1.21 (-0.37%) ▼|GOOGL329.11-1.54 (-0.47%) ▼|GS1,020.92-8.44 (-0.82%) ▼|HD306.26-4.23 (-1.36%) ▼|HON202.20-2.74 (-1.33%) ▼|IBM236.52-3.45 (-1.44%) ▼|INTC101.21-5.03 (-4.73%) ▼|INTU311.27-2.67 (-0.85%) ▼|ISRG349.01-4.23 (-1.20%) ▼|JNJ269.88+2.69 (+1.00%) ▲|JPM353.34-1.35 (-0.38%) ▼|KO88.65+1.07 (+1.22%) ▲|LIN466.67+0.02 (+0.00%) ▲|LLY1,130.15+5.89 (+0.52%) ▲|LMT526.16+1.67 (+0.32%) ▲|LOW196.14-2.47 (-1.24%) ▼|LRCX303.62-12.22 (-3.87%) ▼|MA564.85-2.77 (-0.49%) ▼|MCD254.89+1.35 (+0.53%) ▲|MDLZ62.39-0.04 (-0.06%) ▼|MDT91.36-0.55 (-0.60%) ▼|META653.24-0.45 (-0.07%) ▼|MMM162.71-1.71 (-1.04%) ▼|MO68.81+0.90 (+1.32%) ▲|MRK147.25-0.34 (-0.23%) ▼|MS214.48-0.87 (-0.40%) ▼|MSFT488.14-3.51 (-0.71%) ▼|MU987.89-39.88 (-3.88%) ▼|NEE83.02+0.35 (+0.42%) ▲|NFLX75.10-0.93 (-1.22%) ▼|NKE36.97-0.39 (-1.03%) ▼|NOW131.90+0.79 (+0.60%) ▲|NVDA219.19-4.48 (-2.00%) ▼|ORCL157.72-4.00 (-2.48%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.68-0.11 (-0.38%) ▼|PG143.04+0.37 (+0.26%) ▲|PLTR165.81-3.72 (-2.19%) ▼|PM189.72+4.03 (+2.17%) ▲|QCOM171.81-4.59 (-2.60%) ▼|RTX197.28-0.30 (-0.15%) ▼|SBUX99.90-0.14 (-0.14%) ▼|SCHW107.02+0.48 (+0.45%) ▲|SO88.63+0.28 (+0.32%) ▲|SPG206.05+1.42 (+0.69%) ▲|T25.65+0.49 (+1.95%) ▲|TMO599.60-6.57 (-1.08%) ▼|TMUS178.45+1.11 (+0.63%) ▲|TSLA361.49-6.33 (-1.72%) ▼|TXN257.18-4.41 (-1.69%) ▼|UBER69.68-1.43 (-2.00%) ▼|UNH398.24+5.17 (+1.31%) ▲|UNP287.53+2.74 (+0.96%) ▲|UPS99.38+0.16 (+0.16%) ▲|USB62.24+0.11 (+0.17%) ▲|V366.64-0.94 (-0.26%) ▼|VZ50.51+0.75 (+1.51%) ▲|WFC89.75+0.07 (+0.07%) ▲|WMT107.00+1.17 (+1.10%) ▲|XOM164.83+0.57 (+0.34%) ▲|AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT104.61-0.64 (-0.61%) ▼|ACN175.94+0.10 (+0.06%) ▲|ADBE250.87-4.00 (-1.57%) ▼|AMAT456.67-12.19 (-2.60%) ▼|AMD509.74-11.36 (-2.18%) ▼|AMGN390.18-1.09 (-0.28%) ▼|AMT174.98-0.60 (-0.34%) ▼|AMZN251.14-1.26 (-0.50%) ▼|AVGO359.25-5.13 (-1.41%) ▼|AXP321.15-0.65 (-0.20%) ▼|BA207.29+0.81 (+0.39%) ▲|BAC62.61-0.08 (-0.13%) ▼|BKNG173.65+0.22 (+0.13%) ▲|BLK1,067.32-5.20 (-0.48%) ▼|BMY64.39-0.02 (-0.03%) ▼|BNY162.60+0.03 (+0.02%) ▲|BRK-B507.32+0.56 (+0.11%) ▲|C138.00+0.19 (+0.14%) ▲|CAT809.00-7.05 (-0.86%) ▼|CL88.66+0.65 (+0.73%) ▲|CMCSA24.74+0.15 (+0.61%) ▲|COF209.00-1.95 (-0.92%) ▼|COP137.89+1.28 (+0.94%) ▲|COST910.45+7.85 (+0.87%) ▲|CRM244.22+0.02 (+0.01%) ▲|CSCO109.31-0.12 (-0.11%) ▼|CVS96.74+1.36 (+1.42%) ▲|CVX215.32+1.50 (+0.70%) ▲|DE676.67-0.62 (-0.09%) ▼|DHR200.69-4.30 (-2.10%) ▼|DIS104.09-0.09 (-0.08%) ▼|DUK120.79+0.35 (+0.29%) ▲|EMR148.07-2.33 (-1.55%) ▼|FDX308.33-0.90 (-0.29%) ▼|GD353.93+1.25 (+0.35%) ▲|GE323.99-1.45 (-0.45%) ▼|GEV937.18-13.43 (-1.41%) ▼|GILD145.60-0.06 (-0.04%) ▼|GM84.25+0.47 (+0.56%) ▲|GOOG327.17-1.21 (-0.37%) ▼|GOOGL329.11-1.54 (-0.47%) ▼|GS1,020.92-8.44 (-0.82%) ▼|HD306.26-4.23 (-1.36%) ▼|HON202.20-2.74 (-1.33%) ▼|IBM236.52-3.45 (-1.44%) ▼|INTC101.21-5.03 (-4.73%) ▼|INTU311.27-2.67 (-0.85%) ▼|ISRG349.01-4.23 (-1.20%) ▼|JNJ269.88+2.69 (+1.00%) ▲|JPM353.34-1.35 (-0.38%) ▼|KO88.65+1.07 (+1.22%) ▲|LIN466.67+0.02 (+0.00%) ▲|LLY1,130.15+5.89 (+0.52%) ▲|LMT526.16+1.67 (+0.32%) ▲|LOW196.14-2.47 (-1.24%) ▼|LRCX303.62-12.22 (-3.87%) ▼|MA564.85-2.77 (-0.49%) ▼|MCD254.89+1.35 (+0.53%) ▲|MDLZ62.39-0.04 (-0.06%) ▼|MDT91.36-0.55 (-0.60%) ▼|META653.24-0.45 (-0.07%) ▼|MMM162.71-1.71 (-1.04%) ▼|MO68.81+0.90 (+1.32%) ▲|MRK147.25-0.34 (-0.23%) ▼|MS214.48-0.87 (-0.40%) ▼|MSFT488.14-3.51 (-0.71%) ▼|MU987.89-39.88 (-3.88%) ▼|NEE83.02+0.35 (+0.42%) ▲|NFLX75.10-0.93 (-1.22%) ▼|NKE36.97-0.39 (-1.03%) ▼|NOW131.90+0.79 (+0.60%) ▲|NVDA219.19-4.48 (-2.00%) ▼|ORCL157.72-4.00 (-2.48%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.68-0.11 (-0.38%) ▼|PG143.04+0.37 (+0.26%) ▲|PLTR165.81-3.72 (-2.19%) ▼|PM189.72+4.03 (+2.17%) ▲|QCOM171.81-4.59 (-2.60%) ▼|RTX197.28-0.30 (-0.15%) ▼|SBUX99.90-0.14 (-0.14%) ▼|SCHW107.02+0.48 (+0.45%) ▲|SO88.63+0.28 (+0.32%) ▲|SPG206.05+1.42 (+0.69%) ▲|T25.65+0.49 (+1.95%) ▲|TMO599.60-6.57 (-1.08%) ▼|TMUS178.45+1.11 (+0.63%) ▲|TSLA361.49-6.33 (-1.72%) ▼|TXN257.18-4.41 (-1.69%) ▼|UBER69.68-1.43 (-2.00%) ▼|UNH398.24+5.17 (+1.31%) ▲|UNP287.53+2.74 (+0.96%) ▲|UPS99.38+0.16 (+0.16%) ▲|USB62.24+0.11 (+0.17%) ▲|V366.64-0.94 (-0.26%) ▼|VZ50.51+0.75 (+1.51%) ▲|WFC89.75+0.07 (+0.07%) ▲|WMT107.00+1.17 (+1.10%) ▲|XOM164.83+0.57 (+0.34%) ▲|
22.8 C
New York
Thursday, September 10, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1releasesmarket

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update.

Empower Your Future: Discover Pfizer’s 5-Year Potential with Jessie Harper

Hey, fabulous money mavens! 🌟 Ready for a quick dive into what the future holds for Pfizer? Let’s break it down, Jessie-style, and see...

Energy Fuels Announces Appointment of President

DENVER , July 31, 2025 /CNW/ - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium, rare earth elements and...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Accuray to Report Fourth Quarter Fiscal 2025 Financial Results on August 13, 2025

MADISON, Wis., July 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2025, ended...

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

Espervita’s EVT0185 Shows Dramatic Tumor Reduction and Immune Activation in Preclinical MASH-Driven Hepatocellular Carcinoma

ANN ARBOR, Mich., July 30, 2025 /PRNewswire/ -- Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Nature featuring groundbreaking...

EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia

-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company...

NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement.

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

COTA partners with LCP Health Analytics to advance the use of US RWD to support HTA decision making internationally

US + UK Data to Address Key Evidence Gaps in Access to Medicines NEW YORK, July 30, 2025 /PRNewswire/ -- LCP Health Analytics is partnering...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers